Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
3.840
-0.130 (-3.27%)
At close: Jan 31, 2025, 4:00 PM
4.000
+0.160 (4.17%)
After-hours: Jan 31, 2025, 6:29 PM EST
Larimar Therapeutics Employees
Larimar Therapeutics had 42 employees as of December 31, 2023. The number of employees increased by 16 or 61.54% compared to the previous year.
Employees
42
Change (1Y)
16
Growth (1Y)
61.54%
Revenue / Employee
n/a
Profits / Employee
-$1,542,214
Market Cap
245.02M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42 | 16 | 61.54% |
Dec 31, 2022 | 26 | -5 | -16.13% |
Dec 31, 2021 | 31 | 3 | 10.71% |
Dec 31, 2020 | 28 | 12 | 75.00% |
Dec 31, 2019 | 16 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
LRMR News
- 9 days ago - Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - GlobeNewsWire
- 4 weeks ago - Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better - Seeking Alpha
- 6 weeks ago - What's Going On With Larimar Therapeutics Stock On Tuesday? - Benzinga
- 6 weeks ago - Why Is Larimar Therapeutics Stock Trading Lower On Monday? - Benzinga
- 6 weeks ago - Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia - GlobeNewsWire
- 3 months ago - Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 3 months ago - Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga
- 4 months ago - Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential - Seeking Alpha